Inside the NIH’s controversial decision to stop its big remdesivir study
YANA PASKOVA/GETTY IMAGES
At the heart of the decision was a process that was — as is often in the case in clinical trials — by turns secretive and bureaucratic.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario